Loxo Oncology, Inc.·4

Dec 12, 5:14 PM ET

Burstein Jennifer 4

4 · Loxo Oncology, Inc. · Filed Dec 12, 2018

Insider Transaction Report

Form 4
Period: 2018-12-10
Burstein Jennifer
Vice President of Finance
Transactions
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2018-12-101,25018,750 total
    Exercise: $11.35Exp: 2025-04-30Common Stock (1,250 underlying)
  • Exercise/Conversion

    Common Stock

    2018-12-10$11.35/sh+1,250$14,1881,250 total
  • Sale

    Common Stock

    2018-12-10$130.79/sh100$13,0791,150 total
  • Sale

    Common Stock

    2018-12-10$132.44/sh400$52,976750 total
  • Sale

    Common Stock

    2018-12-10$133.34/sh100$13,334650 total
  • Sale

    Common Stock

    2018-12-10$134.71/sh550$74,091100 total
  • Sale

    Common Stock

    2018-12-10$136.04/sh100$13,6040 total
  • Exercise/Conversion

    Common Stock

    2018-12-11$11.35/sh+1,250$14,1881,250 total
  • Sale

    Common Stock

    2018-12-11$135.69/sh200$27,1381,050 total
  • Sale

    Common Stock

    2018-12-11$136.98/sh587$80,407463 total
  • Sale

    Common Stock

    2018-12-11$137.88/sh263$36,262200 total
  • Sale

    Common Stock

    2018-12-11$139.36/sh100$13,936100 total
  • Sale

    Common Stock

    2018-12-11$140.48/sh100$14,0480 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2018-12-111,25017,500 total
    Exercise: $11.35Exp: 2025-04-30Common Stock (1,250 underlying)
Footnotes (8)
  • [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  • [F2]Represents the aggregate of sales effected on the same day at different prices.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.20 to $132.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.40 to $135.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.28 to $136.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F7]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.50 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F8]The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, May 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4